CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report First Quarter 2022 Financial Results

CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients

International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair

CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR

CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that as part of its investment in health equity improvements, it is contributing to a new program led by UC Davis Health that aims to improve knowledge about and access to organ donation and transplantation in underserved communities throughout California.

CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation

Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions

CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States

CareDx Reports Over 200,000 Heart Transplant Patient Results Served

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 10, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

CareDx Update

Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health

CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 3, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

CareDx Shareholder Alert

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.

CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the HeartBrothers Foundation as a corporate member and also hosting a patient education webinar together. HeartBrothers is a non-profit organization dedicated to helping patients with heart failure, including those receiving heart transplants, navigate their heart-related challenges.

CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant

New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant

CareDx's AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology

UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful

CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 14, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

CareDx Shareholder Update

CareDx Also Hosting Educational Webinar “Innovations in Kidney Care” to Help Improve the Pre- and Post-Transplant Journey for Patients CareDx Also Hosting Educational Webinar “Innovations in Kidney Care” to Help Improve the Pre- and Post-Transplant Journey for Patients

CareDx Partners with the National Kidney Foundation to Advocate for Kidney Transplant Patients

CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the fourth quarter and full year ended December 31, 2021.

CareDx Reports Fourth Quarter and Full Year 2021 Results

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report Fourth Quarter and Full Year 2021 Financial Results

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need

On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant

CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure

CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Raymond James 43rd Annual Institutional Investors Conference.

CareDx To Participate In Upcoming Conferences

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients

Landmark ADMIRAL Study Publication with CareDx's AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

The stock price of CareDx, Inc. (Nasdaq: CDNA) increased by 18.48% in the most recent trading session. This is why it happened.

CareDx Stock (CDNA): Why The Price Surged Today

ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic

News for CareDx Stock (CDNA)